Trade Mark Journal No.2026/043 23 October 2026
WO0000001926124 (1,9,10,42,44)
Office of origin: United States of America
Date of International Registration:7 October 2025
Date of designation in the UK:
7 October 2025
International priority date claimed: 10 April 2025
(United States of America)
(99130323)
International priority date claimed: 10 April 2025
(United States of America)
(99130328)
International priority date claimed: 10 April 2025
(United States of America)
(99130334)
International priority date claimed: 10 April 2025
(United States of America)
(99130340)
International priority date claimed: 10 April 2025
(United States of America)
(99130344)
- Class 1
- Biocompatible plasmonic and magnetoelectric nanoparticles being active chemical ingredients / biochemical products, other than for medical purposes, for use in brain-computer interface (BCI) systems that are used for integration with human brain tissue to enable non-invasive stimulation and recording of neural activity and for real-time diagnostics for enhanced neurological treatments.
- Class 9
- Wearable electronic devices and brain-computer interface (BCI) systems featuring biocompatible nanoparticles for the stimulation and recording of neural activity, signal capture and transmission, thought-controlled digital device interaction, enhanced human-machine integration, real-time brain activity monitoring, cognitive function enhancement, cognitive rehabilitation therapies, and improved accessibility for individuals with physical limitations; downloadable and recorded software for use with brain-computer interface (BCI) devices and systems, enabling non-invasive neural activity stimulation and recording, signal capture and transmission, thought-controlled digital device interaction, enhanced human-machine integration, real-time brain activity monitoring, cognitive function enhancement, cognitive rehabilitation therapies, and improved accessibility for individuals with physical limitations; downloadable mobile applications for use with brain-computer interface (BCI) devices and systems, facilitating non-invasive neural activity stimulation and recording, signal capture and transmission, thought-controlled digital device interaction, enhanced human-machine integration, real-time brain activity monitoring, cognitive function enhancement, cognitive rehabilitation therapies, and improved accessibility for individuals with physical limitations; downloadable software development kits (SDKs) for creating applications that utilize brain-computer interface (BCI) technology for neurological treatment and human-machine interaction.
- Class 10
- Medical devices featuring non-surgical, biocompatible nanoparticles for the treatment of neurological and neurodegenerative diseases through targeted brain stimulation; brain-computer interface devices for medical use, designed to restore motor functions and enhance cognitive rehabilitation therapies; health monitoring devices utilizing brain-computer interface (BCI) technology for real-time brain activity analysis and diagnostics, aiding in the treatment and understanding of neurological disorders; devices for providing neurofeedback and biofeedback, supporting therapeutic interventions and cognitive enhancement.
- Class 42
- Software as a service (SaaS) services featuring non-downloadable software for use with brain-computer interface (BCI) devices and systems, enabling non-invasive neural activity stimulation and recording, signal capture and transmission, thought-controlled digital device interaction, enhanced human-machine integration, real-time brain activity monitoring, cognitive function enhancement, cognitive rehabilitation therapies, and improved accessibility for individuals with physical limitations; research and development services in the field of brain-computer interfaces and biocompatible nanoparticle technology for enhancing human cognition and interaction with technology; providing technology-based services utilizing brain-computer interface (BCI) systems for real-time neural activity monitoring, aiding in the early detection and diagnosis of neurological conditions; software design and development services for brain-computer interface (BCI) applications, including those for medical treatment, cognitive enhancement, and human-machine interaction; technology consultation in the fields of brain-computer interface (BCI) and biocompatible nanoparticle technology, focusing on non-invasive methods for neural stimulation and recording.
- Class 44
- Providing medical and therapeutic services using non-invasive brain-computer interface (BCI) technology, including neurofeedback, cognitive enhancement, and brain health monitoring; health monitoring and diagnostic services involving brain-computer interface (BCI) technology for the detection, diagnosis, and treatment of neurological conditions; medical consultation services utilizing brain-computer interface (BCI) technology for enhancing treatment plans and cognitive rehabilitation therapies.
Subsense, Inc.
Representative: Kristin S. Cornuelle Orrick, Herrington & Sutcliffe LLP, 2050 Main Street, Suite 1100, Irvine CA 92614, UNITED STATES OF AMERICA